EUROPEAN INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH AND MANAGEMENT STUDIES

VOLUME04 ISSUE08
DOI: https://doi.org/10.55640/eijmrms-04-08-03 Pages: 25-30

GENETIC MECHANISMS OF OSTEOARTHRITIS OF THE FEMORAL HIP JOINT

Shodikulova Gulandom Zikriyayevna
Professor, Samarkand State Medical University, Samarkand, Uzbekistan

Gulomov Jahongir Ibrokhimovich
Assistant, Samarkand State Medical University, Samarkand, Uzbekistan

Pulatov Ulugbek Sunatovich
PhD, docent, Samarkand State Medical University, Samarkand, Uzbekistan

Khasanov Oybek Gafurovich
Assistant, Samarkand State Medical University, Samarkand, Uzbekistan

ABOUT ARTICLE

Key words: Osteoarthritis (OA), genetic mechanisms, COVID-19, SARS-CoV-2 virus, femoral hip joint, genes encoding collagen (e.g., COL2A1), GDF5, Medications targeting molecular targets, Cartilage metabolism genes, matrix metalloproteinases (MMPs) and their inhibitors (TIMPs).

Received: 02.08.2024
Accepted: 07.08.2024
Published: 12.08.2024

Abstract: Osteoarthritis of the hip is a prevalent degenerative joint disease characterized by various genetic and environmental influences. This review emphasizes the contributions of key genetic mechanisms, particularly the COL2A1 and GDF5 genes, to cartilage damage and the pathogenesis of osteoarthritis. Genetic mutations, polymorphisms, and variations in these genes are linked to heightened risks and more severe clinical presentations of osteoarthritis, especially in patients following COVID-19. Furthermore, additional genes involved in inflammatory responses and cartilage metabolism also play a crucial role in disease development. The insights gained from genetic research may lead to innovative approaches to early diagnosis, personalized treatment plans, and improved management strategies for osteoarthritis. Future studies utilizing larger patient cohorts and advanced genetic analysis methods are essential to confirm these findings and enhance understanding of osteoarthritis, ultimately improving preventive and therapeutic interventions.

INTRODUCTION

Osteoarthritis of the hip is a multifactorial disease, with a variety of genetic and environmental factors involved in its development. Some genetic mechanisms that contribute to joint cartilage damage and the development of osteoarthritis include:

Genetic predisposition: Studies show that heredity plays an important role in the risk of developing osteoarthritis. Genetic mutations that manifest in osteoarthritis, such as mutations in genes encoding collagen (e.g., COL2A1), aggrecan, and other extracellular matrix proteins, have been identified.

COL2A1 gene: This gene encodes a type of collagen II, which is a major component of cartilage tissue. Mutations in the COL2A1 gene can lead to impaired collagen structure and function, which in turn affects the integrity and stability of cartilage tissue. This can accelerate cartilage damage, a key aspect of osteoarthritis.

Collagen genes: Mutations in genes encoding different types of collagen can affect the strength and elasticity of cartilage, making it more susceptible to damage and degeneration.

GDF5 gene: This gene encodes growth and differentiation factor 5, which is involved in the development and maintenance of connective tissues. Mutations in this gene may increase the risk of developing osteoarthritis. GDF5 is involved in the growth and development of bones and joints. Mutations or genetic changes in GDF5 can interfere with normal joint development and contribute to the development of osteoarthritis. This gene is also involved in tissue repair and regeneration processes, so disrupting it can make it difficult for cartilage to naturally regenerate after damage.

These two genes, COL2A1 and GDF5, have attracted particular attention from researchers because they play an important role in the structure and function of articular cartilage, as well as in bone remodelling processes. Studying the role of these genes helps to understand the pathogenesis of osteoarthritis in patients after COVID-19. The COL2A1 gene encodes the α-chain of type I collagen, which is a major component of connective tissue and articular cartilage. Various polymorphisms of the COL2A1 gene are associated with the risk of osteoarthritis and its progression. In one study, the COL2A1 gene polymorphism (rs1800012) was associated with an increased risk of osteoarthritis. In addition, some studies show an association between COL2A1 genetic variants and more severe clinical manifestations of osteoarthritis, such as reduced articular cartilage thickness and osteophytes.

The GDF5 (growth and differentiation factor 5) gene is a key regulator of joint and cartilage development. Different genetic variants of GDF5 are associated with the risk of osteoarthritis and its clinical manifestations. One study has shown that certain GDF5 polymorphisms are associated with an increased risk of osteoarthritis. Other studies show an association between GDF5 genetic variants and characteristics of osteoarthritis, such as the development of joint changes and the severity of clinical symptoms. This confirms the role of GDF5 in the pathogenesis of osteoarthritis and its possible influence on osteoarthritis characteristics in COVID-19 patients.

Studies on the role of COL2A1 and GDF5 genes in the characteristics of hip osteoarthritis in patients after COVID-19 are relatively new and require additional studies to confirm and clarify the findings. However, preliminary data indicate a possible influence of these genes on the risk of osteoarthritis and its clinical manifestations in these patients.

To better understand the role of COL2A1 and GDF5 genes in the characteristics of osteoarthritis in patients after COVID-19, further studies using large patient samples and different methods of genetic variant analysis are needed. This will allow the development of more accurate approaches to diagnosis, treatment and prognosis of osteoarthritis in a certain group of patients.

Genes regulating inflammation: inflammation plays a key role in the pathogenesis of osteoarthritis. Alterations in genes involved in inflammatory processes, such as the interleukin or TNF-α genes, may contribute to the development of the disease.

Cartilage metabolism genes: Abnormalities in genes that regulate the synthesis and degradation of cartilage components, such as matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), can lead to imbalances in the maintenance of cartilage integrity.

FRZB gene: This gene encodes a protein that regulates bone growth and development by acting on cartilage through WNT signaling pathways. Mutations in FRZB can contribute to cartilage abnormalities and the development of osteoarthritis.

ADAMTS5 gene: This gene encodes an enzyme involved in the degradation of aggrecan, a major component of cartilage.

IL1 and TNF genes: These genes encode inflammatory cytokines that may play a role in the pathogenesis of osteoarthritis by promoting inflammation and cartilage destruction.

Changes in genes related to body weight and height: Obesity is a significant risk factor for osteoarthritis, so genes that affect body weight and metabolism (e.g. leptin genes) may also play a role in the development of this condition.

Epigenetic changes: Specific mutations and epigenetic modifications such as DNA methylation and histone modification can also influence the development of osteoarthritis.

Understanding the genetic factors that influence the development of osteoarthritis of the hip may lead to innovations in the diagnosis and treatment of this disease in the future:

- Genetic research: it can help doctors identify patients at high risk of developing osteoarthritis before symptoms appear. This will open up opportunities for early prevention, including lifestyle, dietary, and physical activity changes that can slow or prevent the disease from developing.

- Medications targeting molecular targets: Medications designed to target different molecular targets identified through genetic studies may be a new direction in the treatment of osteoarthritis. Such drugs may include metalloproteinase inhibitors, agents that modulate neuronal signaling pathways, or biologics that stimulate growth factors and cytokines.

- Developments in regenerative medicine: The use of stem cells and tissue engineering to repair damaged cartilage can be improved using genetic information. For example, gene therapy can be used to correct cartilage defects or stimulate cartilage regeneration at the molecular level.

- Disease biomarkers: Identifying biomarkers that may indicate osteoarthritis activity will allow physicians to better monitor disease progression and treatment efficacy.

- Targeted nutritional supplements: Biologically active substances such as chondroitin, glucosamine, or omega-3 fatty acids can be personalized based on a patient's genetic profile to improve joint health and slow degenerative processes.

- Personalised exercise: Different types of exercise can be preferred based on the patient's genetic profile to maximize the benefits of exercise and minimize the risk of joint damage.

- Personalised medication: Knowledge of genetic factors can help predict response to analgesics and anti-inflammatory drugs, allowing individualization of pain management and management of side effects.

CONCLUSION

Thus, osteoarthritis of the hip is a complex, multifactorial condition influenced significantly by genetic predispositions and environmental factors. Recent studies highlight the pivotal roles of specific genes, particularly COL2A1 and GDF5, in cartilage integrity, joint development, and the overall progression of osteoarthritis. Genetic variations in these genes have been associated with increased susceptibility to the disease, its severity, and clinical manifestations, especially in patients following COVID-19. Additionally, the involvement of other inflammatory and cartilage metabolism-related genes further complicates the pathogenesis of hip osteoarthritis. Understanding these genetic factors offers promising insights into the potential for early diagnosis, targeted therapies, and personalized medicine strategies for osteoarthritis management, paving the way for advancements in prevention and treatment protocols.

REFERENCES

1. Coaccioli S. et al. Osteoarthritis: New insight on its pathophysiology //Journal of Clinical Medicine. – 2022. – T. 11. – №. 20. – C. 6013.
2. Chow YY, Chin KY. The Role of Inflammation in the Pathogenesis of Osteoarthritis. Mediators Inflamm. 2020 Mar 3;2020:8293921. doi: 10.1155/2020/8293921. PMID: 32189997; PMCID: PMC7072120.
3. Endstrasser F, Braito M, Linser M, Spicher A, Wagner M, Brunner A. The negative impact of the COVID-19 lockdown on pain and physical function in patients with end-stage hip or knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2020 Aug;28(8):2435-2443. doi: 10.1007/s00167-020-06104-3. Epub 2020 Jun 18. PMID: 32556438; PMCID: PMC7299668.
4. Katz J. N., Arant K. R., Loeser R. F. Diagnosis and treatment of hip and knee osteoarthritis: a review //Jama. – 2021. – T. 325. – №. 6. – C. 568-578.
5. Khella C. M. et al. An evidence-based systematic review of human knee post-traumatic osteoarthritis (PTOA): timeline of clinical presentation and disease markers, comparison of knee joint PTOA models and early disease implications //International Journal of Molecular Sciences. – 2021. – T. 22. – №. 4. – C. 1996.
6. Kijima H. et al. The differences in imaging findings between painless and painful osteoarthritis of the hip //Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. – 2020. – T. 13. – C. 1179544120946747.
7. Motta F. et al. Inflammaging and osteoarthritis //Clinical Reviews in Allergy & Immunology. – 2023. – T. 64. – №. 2. – C. 222-238.

8. Shodikulova G. Z. et al. The Correlation among Osteoporosis, Calcium-Phosphore Metabolism and Clinical Symptoms of Main Disease in Patients with Rheumatoid Arthritis //Annals of the Romanian Society for Cell Biology. – 2021. – С. 4185-4190.

9. Trivanovic D. et al. Immune and stem cell compartments of acetabular and femoral bone marrow in hip osteoarthritis patients //Osteoarthritis and Cartilage. – 2022. – Т. 30. – №. 8. – С. 1116-1129.

10. Zikriyayevna S. G. et al. HEART RHYTHM DISTURBANCES IN CONNECTIVE TISSUE DYSPLASIA //International Journal of Medical Sciences And Clinical Research. – 2024. – Т. 4. – №. 06. – С. 32-39.

11. Zikriyayevna S. G. et al. FUNCTIONAL COMPONENT OF THE CARDIOVASCULAR SYSTEM IN INDIVIDUALS WITH CONNECTIVE TISSUE DYSPLASIA //International Journal of Medical Sciences And Clinical Research. – 2024. – Т. 4. – №. 06. – С. 24-31.

12. Киямова Л. и др. СОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ СИНДРОМА ГИПЕРАКТИВНОГО МОЧЕВОГО ПУЗЫРЯ //Models and methods in modern science. – 2024. – Т. 3. – №. 1. – С. 237-243.

13. Киямова Л. и др. ДИАГНОСТИКА СИНДРОМА ГИПЕРАКТИВНОГО МОЧЕВОГО ПУЗЫРЯ //Theoretical aspects in the formation of pedagogical sciences. – 2024. – Т. 3. – №. 2. – С. 138-145.

14. Киямова Л. и др. ОСОБЕННОСТИ ТЕЧЕНИЯ ОСЛОЖНЕННОГО ГЕСТАЦИОННОГО ПИЕЛОНЕФРИТА У БЕРЕМЕННЫХ //Solution of social problems in management and economy. – 2024. – Т. 3. – №. 1. – С. 194-201.

15. Пулатов У. С., Суюнов А. Ф. ПОЛИМОРФИЗМ ГАПТОГЛОБИНА У БОЛЬНЫХ С РЕВМАТОИДНЫМ АРТИРОМ //" Conference on Universal Science Research 2023". – 2023. – Т. 1. – №. 2. – С. 120-123.

16. Пулатов У., Нематуллаев Ж., Шопулотова З. ОСТРЫЕ РЕСПИРАТОРНЫЕ ВИРУСНЫЕ ИНФЕКЦИИ: СИМПТОМЫ, ЛЕЧЕНИЕ И ПРОФИЛАКТИКА //Евразийский журнал медицинских и естественных наук. – 2024. – Т. 4. – №. 5. – С. 269-273.

17. Пулатов У. С. и др. ОСОБЕННОСТИ ЛЕЧЕНИЯ ПРИ ХПН //INNOVATIVE DEVELOPMENTS AND RESEARCH IN EDUCATION. – 2023. – Т. 2. – №. 23. – С. 303-305.

18. Шодикулова Г. З. и др. СОВРЕМЕННЫЙ ВЗГЛЯД НА ПРОБЛЕМУ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ У БОЛЬНЫХ С ПОДАГРОЙ И БЕССИМПТОМНОЙ ГИПЕРУРИКЕМИЕЙ //Journal of cardiorespiratory research. – 2023. – Т. 1. – №. 1. – С. 28-33.

19. Шодикулова Г. З., Мирзаев О. В., Саматов Д. К. РАСПРОСТРАНЕННОСТЬ И КЛИНИКО-ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ ДИСПЛАЗИИ СОЕДИНИТЕЛЬНОЙ ТКАНИ У ЛИЦ УЗБЕКСКОЙ ПОПУЛЯЦИИ //Journal of cardiorespiratory research. – 2023. – Т. 1. – №. 1. – С. 94-98.